Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OMEGA-1: AL-335, Odalasvir, and Simeprevir in Chronic HCV
NCT02765490Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2016
- Primary completion
- Aug 2017
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of adafosbuvir, odalasvir, simeprevir in hepatitis C (HCV), sponsored by Janssen Pharmaceutical. Started Nov 2016; status: completed.
02
Drugs
adafosbuvirodalasvirsimeprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02765490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02765490.